Loading publications…
The last 5 uploaded publications
Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.
Gerhardt Attard, Neeraj Agarwal, Julie N. Graff, Shahneen Sandhu, Eleni Efstathiou, Mustafa Özgüroğlu, Andrea Juliana Gomes, Karina Costa Maia Vianna, Hong Luo, Heather H. Cheng, Won Bae Kim, Carlos Federico Varela, Daneen Schaeffer, Shiva Dibaj, Susan Li, Fei Shen, Suneel Mundle, David Olmos, Kim N., Dana E. Rathkopf (2025). Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.. , 43(17_suppl), DOI: https://doi.org/10.1200/jco.2025.43.17_suppl.lba5006.
Article63 days agoAMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC).
Dana E. Rathkopf, Kim N., David Olmos, Heather H. Cheng, Neeraj Agarwal, Julie N. Graff, Shahneen Sandhu, Vinny Hayreh, Angela Lopez‐Gitlitz, Peter Francis, Gerhardt Attard (2021). AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC).. , 39(6_suppl), DOI: https://doi.org/10.1200/jco.2021.39.6_suppl.tps176.
Article63 days ago